Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesofensine/Metoprolol in Prader-Willi Syndrome
NCT03149445Phase 2Completed
- Sponsor
- Saniona
- Start
- Mar 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Prader-Willi syndrome (PWS) comparing Tesofensine/Metoprolol with Placebo (2 arms). Primary endpoint: Percent Change From Baseline to End of Treatment in Mean Body Weight at 271 days. Started Mar 2017; status: completed.
02
Drugs
tesofensine
03
Conditions
Prader-Willi syndrome (PWS)
Beyond the preview
Go deeper on NCT03149445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03149445.